Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Abdominal Radiology
Published in: Abdominal Radiology 12/2021

01-12-2021 | Magnetic Resonance Imaging | Review

Tumor in vein (LR-TIV) and liver imaging reporting and data system (LI-RADS) v2018: diagnostic features, pitfalls, prognostic and management implications

Authors: Roberta Catania, Kalina Chupetlovska, Amir A. Borhani, Ekta Maheshwari, Alessandro Furlan

Published in: Abdominal Radiology | Issue 12/2021

Login to get access

Abstract

Vascular invasion by hepatocellular carcinoma (HCC), also known as tumor in vein (TIV), indicates highly invasive tumor behavior and is also associated with poor outcome. Because a diagnosis of TIV precludes liver transplantation, knowledge of the imaging findings to differentiate between TIV and bland thrombus is key for proper patient management. Prior versions of liver imaging reporting and data system (LI-RADS) included presence of TIV as part of LR-5 criteria. However, even if HCC is the most common liver malignancy associated with TIV, other tumors can have vascular invasion and may occur in cirrhotic patients. For these reasons, in LI-RADS v2017 LR-TIV has been introduced as a new different diagnostic category. The aim of this article is to discuss the diagnostic criteria of LR-TIV according to LI-RADS v2018 and analyze potential pitfalls encountered on daily clinical practice. Indeterminate cases and how to manage them will also be discussed.
Literature
1.
Centers for Disease, C. and Prevention, Hepatocellular carcinoma - United States, 2001-2006. MMWR Morb Mortal Wkly Rep, 2010. 59(17): p. 517-20.
2.
Kulik, L. and H.B. El-Serag, Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology, 2019. 156(2): p. 477-491 e1.PubMed
3.
Ferlay, J., et al., Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer, 2015. 136(5): p. E359-86.PubMed
4.
Singal, A.G. and H.B. El-Serag, Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice. Clin Gastroenterol Hepatol, 2015. 13(12): p. 2140-51.PubMedPubMedCentral
5.
Stepanova, M., et al., Direct and Indirect Economic Burden of Chronic Liver Disease in the United States. Clin Gastroenterol Hepatol, 2017. 15(5): p. 759-766 e5.PubMed
6.
Marrero, J.A., et al., Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology, 2018. 68(2): p. 723-750.PubMed
7.
Baheti, A.D., et al., Clinical implications for imaging of vascular invasion in hepatocellular carcinoma. Abdom Radiol (NY), 2016. 41(9): p. 1800-10.
8.
Mahringer-Kunz, A., et al., Extent of portal vein tumour thrombosis in patients with hepatocellular carcinoma: The more, the worse? Liver Int, 2019. 39(2): p. 324-331.PubMed
9.
European Association for the Study of the Liver. Electronic address, e.e.e. and L. European Association for the Study of the, EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol, 2018. 69(1): p. 182-236.
10.
Heimbach, J.K., et al., AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology, 2018. 67(1): p. 358-380.PubMed
11.
12.
Purysko, A.S., et al., LI-RADS: a case-based review of the new categorization of liver findings in patients with end-stage liver disease. Radiographics, 2012. 32(7): p. 1977-95.PubMed
13.
14.
15.
16.
Roayaie, S., et al., A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology, 2009. 137(3): p. 850-5.PubMed
17.
Huang, C., et al., Microvascular invasion has limited clinical values in hepatocellular carcinoma patients at Barcelona Clinic Liver Cancer (BCLC) stages 0 or B. BMC Cancer, 2017. 17(1): p. 58.PubMedPubMedCentral
18.
Lauwers, G.Y., et al., Prognostic histologic indicators of curatively resected hepatocellular carcinomas: a multi-institutional analysis of 425 patients with definition of a histologic prognostic index. Am J Surg Pathol, 2002. 26(1): p. 25-34.PubMed
19.
20.
Nishie, A., et al., Radiologic detectability of minute portal venous invasion in hepatocellular carcinoma. AJR Am J Roentgenol, 2008. 190(1): p. 81-7.PubMed
21.
Chou, C.T., et al., Prediction of microvascular invasion of hepatocellular carcinoma: preoperative CT and histopathologic correlation. AJR Am J Roentgenol, 2014. 203(3): p. W253-9.PubMed
22.
Min, J.H., et al., Interobserver Variability and Diagnostic Performance of Gadoxetic Acid-enhanced MRI for Predicting Microvascular Invasion in Hepatocellular Carcinoma. Radiology, 2020. 297(3): p. 573-581.PubMed
23.
Zhu, Y.J., et al., Model-based three-dimensional texture analysis of contrast-enhanced magnetic resonance imaging as a potential tool for preoperative prediction of microvascular invasion in hepatocellular carcinoma. Oncol Lett, 2019. 18(1): p. 720-732.PubMedPubMedCentral
24.
Banerjee, S., et al., A computed tomography radiogenomic biomarker predicts microvascular invasion and clinical outcomes in hepatocellular carcinoma. Hepatology, 2015. 62(3): p. 792-800.PubMed
25.
Ma, X., et al., Preoperative radiomics nomogram for microvascular invasion prediction in hepatocellular carcinoma using contrast-enhanced CT. Eur Radiol, 2019. 29(7): p. 3595-3605.PubMed
26.
Hu, H.T., et al., Ultrasound-based radiomics score: a potential biomarker for the prediction of microvascular invasion in hepatocellular carcinoma. Eur Radiol, 2019. 29(6): p. 2890-2901.PubMed
27.
Cuccurullo, V., et al., Microvascular Invasion in HCC: The Molecular Imaging Perspective. Contrast Media Mol Imaging, 2018. 2018: p. 9487938.PubMedPubMedCentral
28.
Pirisi, M., et al., Portal vein thrombosis in hepatocellular carcinoma: age and sex distribution in an autopsy study. J Cancer Res Clin Oncol, 1998. 124(7): p. 397-400.PubMed
29.
Ohnishi, K., et al., Portal venous hemodynamics in hepatocellular carcinoma. Effects of hepatic artery embolization. Gastroenterology, 1987. 93(3): p. 591-6.PubMed
30.
Tsai, T.J., et al., Clinical significance of microscopic tumor venous invasion in patients with resectable hepatocellular carcinoma. Surgery, 2000. 127(6): p. 603-8.PubMed
31.
Roayaie, S., et al., Resection of hepatocellular carcinoma with macroscopic vascular invasion. Ann Surg Oncol, 2013. 20(12): p. 3754-60.PubMed
32.
Jiang, J.F., et al., Treatment of hepatocellular carcinoma with portal vein tumor thrombus: advances and challenges. Oncotarget, 2017. 8(20): p. 33911-33921.PubMedPubMedCentral
33.
Shi, J., et al., Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus. Ann Surg Oncol, 2010. 17(8): p. 2073-80.PubMed
34.
35.
Cerrito, L., et al., Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers. World J Gastroenterol, 2019. 25(31): p. 4360-4382.PubMedPubMedCentral
36.
Yin, J., et al., New Evidence and Perspectives on the Management of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. J Clin Transl Hepatol, 2017. 5(2): p. 169-176.PubMedPubMedCentral
37.
38.
39.
Fraum, T.J., et al., Differentiation of Hepatocellular Carcinoma from Other Hepatic Malignancies in Patients at Risk: Diagnostic Performance of the Liver Imaging Reporting and Data System Version 2014. Radiology, 2018. 286(1): p. 158-172.PubMed
40.
Ronot, M., et al., Comparison of the accuracy of AASLD and LI-RADS criteria for the non-invasive diagnosis of HCC smaller than 3cm. J Hepatol, 2018. 68(4): p. 715-723.PubMed
41.
van der Pol, C.B., et al., Accuracy of the Liver Imaging Reporting and Data System in Computed Tomography and Magnetic Resonance Image Analysis of Hepatocellular Carcinoma or Overall Malignancy-A Systematic Review. Gastroenterology, 2019. 156(4): p. 976-986.PubMed
42.
43.
Kim, J.H., et al., Portal Vein Thrombosis in Patients with Hepatocellular Carcinoma: Diagnostic Accuracy of Gadoxetic Acid-enhanced MR Imaging. Radiology, 2016. 279(3): p. 773-83.PubMed
44.
Thompson, S.M., et al., Venous invasion by hepatic tumors: imaging appearance and implications for management. Abdom Radiol (NY), 2018. 43(8): p. 1947-1967.
45.
Catalano, O.A., et al., Differentiation of malignant thrombus from bland thrombus of the portal vein in patients with hepatocellular carcinoma: application of diffusion-weighted MR imaging. Radiology, 2010. 254(1): p. 154-62.PubMed
46.
Sandrasegaran, K., et al., Usefulness of conventional MRI sequences and diffusion-weighted imaging in differentiating malignant from benign portal vein thrombus in cirrhotic patients. AJR Am J Roentgenol, 2013. 201(6): p. 1211-9.PubMed
47.
Tublin, M.E., G.D. Dodd, 3rd, and R.L. Baron, Benign and malignant portal vein thrombosis: differentiation by CT characteristics. AJR Am J Roentgenol, 1997. 168(3): p. 719-23.PubMed
48.
Sereni, C.P., et al., Portal vein thrombus and infiltrative HCC: a pictoral review. Abdom Radiol (NY), 2017. 42(1): p. 159-170.
49.
Reynolds, A.R., et al., Infiltrative hepatocellular carcinoma: what radiologists need to know. Radiographics, 2015. 35(2): p. 371-86.PubMed
50.
Dusenbery, D., G.D. Dodd, 3rd, and B.I. Carr, Percutaneous fine-needle aspiration of portal vein thrombi as a staging technique for hepatocellular carcinoma. Cytologic findings of 46 patients. Cancer, 1995. 75(8): p. 2057-62.PubMed
51.
De Sio, I., et al., Ultrasound-guided fine needle aspiration biopsy of portal vein thrombosis in liver cirrhosis: results in 15 patients. J Gastroenterol Hepatol, 1995. 10(6): p. 662-5.PubMed
52.
Vilana, R., et al., Fine-needle aspiration biopsy of portal vein thrombus: value in detecting malignant thrombosis. AJR Am J Roentgenol, 1993. 160(6): p. 1285-7.PubMed
53.
Rammohan, A., et al., Percutaneous ultrasound-guided fine-needle aspiration of portal vein thrombi as a diagnostic and staging technique for hepatocellular carcinoma. Abdom Imaging, 2013. 38(5): p. 1057-60.PubMed
54.
Piscaglia, F., et al., Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation. Liver Transpl, 2010. 16(5): p. 658-67.PubMed
55.
Chen, J., et al., Contrast-enhanced ultrasound for the characterization of portal vein thrombosis vs tumor-in-vein in HCC patients: a systematic review and meta-analysis. Eur Radiol, 2020. 30(5): p. 2871-2880.PubMedPubMedCentral
56.
Tarantino, L., et al., Diagnosis of benign and malignant portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma: color Doppler US, contrast-enhanced US, and fine-needle biopsy. Abdom Imaging, 2006. 31(5): p. 537-44.PubMed
57.
Rossi, S., et al., Contrast-enhanced ultrasonography and spiral computed tomography in the detection and characterization of portal vein thrombosis complicating hepatocellular carcinoma. Eur Radiol, 2008. 18(8): p. 1749-56.PubMed
58.
Alhasan, A., et al., LI-RADS for CT diagnosis of hepatocellular carcinoma: performance of major and ancillary features. Abdom Radiol (NY), 2019. 44(2): p. 517-528.
59.
Choi, S.H., et al., LI-RADS Classification and Prognosis of Primary Liver Cancers at Gadoxetic Acid-enhanced MRI. Radiology, 2019. 290(2): p. 388-397.PubMed
60.
Lee, S.M., et al., LI-RADS Version 2017 versus Version 2018: Diagnosis of Hepatocellular Carcinoma on Gadoxetate Disodium-enhanced MRI. Radiology, 2019. 292(3): p. 655-663.PubMed
61.
Makoyeva, A., et al., Use of CEUS LI-RADS for the Accurate Diagnosis of Nodules in Patients at Risk for Hepatocellular Carcinoma: A Validation Study. Radiol Imaging Cancer, 2020. 2(2): p. e190014.PubMedPubMedCentral
62.
Ren, A.H., et al., Diagnostic performance of MR for hepatocellular carcinoma based on LI-RADS v2018, compared with v2017. J Magn Reson Imaging, 2019. 50(3): p. 746-755.PubMed
63.
Schellhaas, B., et al., Diagnostic accuracy of contrast-enhanced ultrasound for the differential diagnosis of hepatocellular carcinoma: ESCULAP versus CEUS-LI-RADS. Eur J Gastroenterol Hepatol, 2017. 29(9): p. 1036-1044.PubMed
64.
Tan, Z., et al., Analysis of comparative performance of CEUS and CECT/MR LI-RADS classification: Can CEUS dichotomize LI-RADS indeterminate lesions on CT or MRI? Clin Imaging, 2020. 62: p. 63-68.PubMed
65.
Wang, J.Y., et al., Usefulness of the Contrast-Enhanced Ultrasound Liver Imaging Reporting and Data System in Diagnosing Focal Liver Lesions by Inexperienced Radiologists. J Ultrasound Med, 2020. 39(8): p. 1537-1546.PubMed
Metadata
Title
Tumor in vein (LR-TIV) and liver imaging reporting and data system (LI-RADS) v2018: diagnostic features, pitfalls, prognostic and management implications
Authors
Roberta Catania
Kalina Chupetlovska
Amir A. Borhani
Ekta Maheshwari
Alessandro Furlan
Publication date
01-12-2021
Publisher
Springer US
Published in
Abdominal Radiology / Issue 12/2021
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-021-03270-x

Other articles of this Issue 12/2021

Abdominal Radiology 12/2021 Go to the issue

Practice

Anal fistula at roof of ischiorectal fossa inside levator-ani muscle (RIFIL): a new highly complex anal fistula diagnosed on MRI

Practice

Approaching diversity and inclusion in the radiology department

Interventional Radiology

Value of second opinion subspecialty radiology consultation in suspected abdominal medium vessel vasculitis

Correction

Correction to: Implementation of peer learning conferences throughout a multi‑site abdominal radiology practice

Technical

Diagnostic abdominal MR imaging on a prototype low-field 0.55 T scanner operating at two different gradient strengths

Practice

Role of social and non-social online media: how to properly leverage your internet presence for professional development and research
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits